title: Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis.
authors: Laboratorio Congiunto per le Malattie Mieloproliferative, Università degli Studi di Firenze, Azienda Ospedaliera Universitaria Careggi, Florence, Italy. paola.guglielmelli@unifi.it.
authors: Paola
authors: P
authors: Guglielmelli
authors: Laboratorio Congiunto per le Malattie Mieloproliferative, Università degli Studi di Firenze, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
authors: Giada
authors: G
authors: Rotunno
authors: Laboratorio Congiunto per le Malattie Mieloproliferative, Università degli Studi di Firenze, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
authors: Costanza
authors: C
authors: Bogani
authors: Laboratorio Congiunto per le Malattie Mieloproliferative, Università degli Studi di Firenze, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
authors: Carmela
authors: C
authors: Mannarelli
authors: Department of Clinical and Experimental Biomedical Sciences, Medical Genetics Unit, Meyer University Hospital, Florence, Italy.
authors: Laura
authors: L
authors: Giunti
authors: Department of Clinical and Experimental Biomedical Sciences, Medical Genetics Unit, Meyer University Hospital, Florence, Italy.
authors: Aldesia
authors: A
authors: Provenzano
authors: Department of Clinical and Experimental Biomedical Sciences, Medical Genetics Unit, Meyer University Hospital, Florence, Italy.
authors: Sabrina
authors: S
authors: Giglio
authors: Novartis Pharma AG, Basel, Switzerland.
authors: Matthew
authors: M
authors: Squires
authors: Novartis Pharma AG, Basel, Switzerland.
authors: Viktoriya
authors: V
authors: Stalbovskaya
authors: Novartis Pharma AG, Basel, Switzerland.
authors: Prashanth
authors: P
authors: Gopalakrishna
authors: Laboratorio Congiunto per le Malattie Mieloproliferative, Università degli Studi di Firenze, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
authors: Alessandro M
authors: AM
authors: Vannucchi
mesh_terms: D037282:Calreticulin / Q000235:genetics*; D006801:Humans; D009570:Nitriles; D055728:Primary Myelofibrosis / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D011720:Pyrazoles / Q000008:administration & dosage*; D011743:Pyrimidines; D012189:Retrospective Studies; D013163:Splenomegaly / Q000188:drug therapy; D015996:Survival Rate; D013922:Thrombocytosis / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D037282:Calreticulin; D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib
keywords: CALR; JAK inhibitor; myelofibrosis; myeloproliferative neoplasm; ruxolitinib